Literature DB >> 6759145

Human in vivo antigenic modulation induced by the anti-T cell OKT3 monoclonal antibody.

L Chatenoud, M F Baudrihaye, H Kreis, G Goldstein, J Schindler, J F Bach.   

Abstract

The anti-pan T cell monoclonal antibody OKT3 was administered daily for 2 weeks in four human renal allograft recipients. The antibody induced a dramatic and immediate depletion of peripheral T cells followed by an in vivo antigenic modulation of the OKT3-defined membrane antigen: after three injections, OKT3-treated patients showed a limited but significant number of OKT3- cells of T cell nature (as defined by OKT4 and OKT8) which recovered the OKT3 receptor after an overnight in vitro incubation in the absence of the monoclonal antibody.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6759145     DOI： 10.1002/eji.1830121116

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


  30 in total

1.  Mobility of the human T lymphocyte surface molecules CD3, CD4, and CD8: regulation by a cAMP-dependent pathway.

Authors:  G M Kammer; C A Boehm; S A Rudolph; L A Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

Review 2.  The role of OKT3 in clinical transplantation.

Authors:  D J Norman; M R Leone
Journal:  Pediatr Nephrol       Date:  1991-01       Impact factor: 3.714

Review 3.  New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity.

Authors:  Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner
Journal:  J Neurol Sci       Date:  2008-09-18       Impact factor: 3.181

Review 4.  Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

5.  Activation of human peripheral blood mononuclear cells by anti-T3: killing of tumor target cells coated with anti-target-anti-T3 conjugates.

Authors:  G Jung; C J Honsik; R A Reisfeld; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

Review 6.  Challenges in the pursuit of immune tolerance.

Authors:  Gerald T Nepom; E William St Clair; Laurence A Turka
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

7.  The clinical use of monoclonal anti-T-cell antibodies.

Authors:  J F Bach; L Chatenoud
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

8.  In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

Authors:  K J Parlevliet; I J ten Berge; S L Yong; J Surachno; J M Wilmink; P T Schellekens
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

9.  Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice.

Authors:  L Chatenoud; E Thervet; J Primo; J F Bach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-01-04       Impact factor: 11.205

10.  Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.

Authors:  T E Feasby
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.